Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives

Could the cure for cancer be hiding in your food? Nature's bioactive compounds show immense promise, but they've been failing a critical test—reaching tumors in the body.

Nature's pantry is packed with bioactive compounds that can dial down inflammation, halt rogue cell growth, and even trigger apoptosis—the body's own kill switch for damaged cells. Yet, despite their promise, these molecules often stumble in the clinic: they're poorly absorbed, rapidly broken down, and rarely accumulate where they're needed most: the tumor.

Enter the engineers. Scientists are building sophisticated delivery platforms—lipid nanoparticles, liposomes, micelles, hydrogels, and stimulus-responsive systems—to shield these fragile compounds and guide them precisely to cancer cells. These technologies aim to boost stability, absorption, and tumor specificity, turning a good idea into a viable therapy.

But the road from lab to patient is rocky. While many compounds shine in cell and animal studies, only a handful have reached early clinical trials, where results are inconsistent and often less dramatic than expected. Regulatory hurdles, lack of standardized formulations, and missing predictive biomarkers further slow progress.

Sustainability adds another layer: researchers are valorizing agrifood by-products and using green extraction methods to source these compounds. The future calls for multicenter trials, comparative designs, and clear regulatory guidelines to bridge the gap between promise and practice.

Key Points

• Bioactive compounds modulate apoptosis, inflammation, and cell signaling.
• Nanocarriers improve stability, absorption, and tumor targeting.
• Clinical translation limited; need standardized regulations and biomarkers.